
Opinion|Videos|September 27, 2024
Treatment Landscape for Transplant-Eligible Patients with NDMM
Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Provide a brief overview of first-line treatment options currently available for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
2
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
3
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
4
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
5